Zurich-based preventative health startup Aeon has announced the acquisition of Holsain, a stealth-mode health technology company, as part of its strategy to strengthen its scientific foundation and enhance its precision diagnostics capabilities. The move comes just four months after Aeon secured CHF 7.5 million in seed funding, signaling rapid momentum in its mission to transform early disease detection. As part of the acquisition, Holsain’s founder, Dr. Florian Alexander Huber, has been appointed as Aeon’s Chief Medical Officer.
Building on Scientific and Clinical Expertise
Aeon, founded in 2023, offers a comprehensive preventive health platform combining AI-powered analysis with full-body MRI scans, blood tests, and genetic screening to assess and predict more than 500 diseases and health risks in a single session. The company has already completed over 1,000 MRI scans, generating actionable health insights through an integrated digital report. With Holsain’s expertise now part of its ecosystem, Aeon aims to deepen its clinical and research capabilities, particularly in medical imaging and AI-based phenotyping.
Holsain’s Role in Personalized Health
Holsain brings extensive experience in body composition phenotyping, which involves analyzing muscle, fat, and organ distribution to uncover early indicators of disease. The company has also built strong R&D foundations in AI modeling, advanced MRI protocols, and preventive risk detection. Through this acquisition, Aeon gains access to Holsain’s technology and methodologies, reinforcing its position as a pioneer in multimodal preventive care. The integration aligns with Aeon’s vision of detecting health risks earlier and improving the quality and accuracy of diagnostics.
Leadership Strengthening with Dr. Florian Huber
Following the acquisition, Dr. Huber will lead Aeon’s medical strategy as Chief Medical Officer. His experience in clinical research and imaging-driven diagnostics is expected to guide Aeon’s expansion into deeper preventive insights. “Holsain was founded on the conviction that the composition of our bodies provides valuable clues long before disease begins,” said Dr. Huber. “Joining Aeon creates the opportunity to integrate this knowledge directly into preventive healthcare and make it accessible to many people.”
CEO’s Perspective on the Acquisition
Aeon’s founder and CEO, Tim Seithe, highlighted the strategic significance of this acquisition in advancing the company’s medical and technological capabilities. “With Holsain and Dr. Huber, we gain both scientific depth and clinical excellence,” he said. “Together, we can detect risks earlier, further develop our MRI protocols, and apply AI exactly where it makes the greatest difference — the patient.” This statement underscores Aeon’s focus on leveraging AI and imaging to personalize prevention and treatment at scale.
The acquisition of Holsain marks Aeon’s first corporate expansion milestone and a major step in its goal to redefine preventive healthcare. By combining Holsain’s scientific expertise with Aeon’s data-driven approach, the company is poised to strengthen its leadership in early disease detection and personalized health insights. As Aeon continues to scale, this move positions it at the forefront of a growing movement toward proactive, precision-driven medicine.